Protara Q1 Results and Business Update

 

• Favorable tolerability and anti-tumor activity observed in NMIBC patients treated with TARA-002 in ADVANCED-1 trial
   
• Company plans to initiate ADVANCED-2 trial in BCG-naïve CIS patients and BCG-unresponsive CIS patients in 2H23
   
• Regulatory clearance received from FDA to commence Phase 2 trial of TARA-002 in Lymphatic Malformations; trial expected to initiate in Q423
   
• Continue to expect cash, cash equivalents and investments of $90M as of March 31, 2023 to fund operations into 2025

https://www.biospace.com/article/releases/protara-therapeutics-announces-first-quarter-2023-financial-results-and-business-update/